Streetbeat News

ZVSA

ZyVersa Therapeutics, Inc.

https://www.zyversa.com

Industry

Biotechnology

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Open

0.59

Mkt cap

1.5M

Volume

6.1K

High

0.61

P/E Ratio

-0.07

52-wk high

8.05

Low

0.58

Div yield

N/A

52-wk low

0.58

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) has announced the publication of an article in the peer-reviewed journal Circulation. The article demonstrates the role of inflammasome NLRP3 activation in hypertrophic heart disease induced by mechanical stress. ZyVersa is a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:42 am

The article lists the stocks that have gained and lost in Friday's mid-day session. Notable gainers include Prestige Wealth Inc., Gorilla Technology Group Inc., and Bluejay Diagnostics, Inc. among others. On the other hand, EdtechX Holdings Acquisition Corp. II, FOXO Technologies Inc., and Alpine Summit Energy Partners, Inc. are among the notable losers. The article also mentions that iMedia Brands, Inc. received a delisting notice from Nasdaq following its Chapter 11 filing.

Portfolio Pulse from Lisa Levin

July 07, 2023 | 4:55 pm

During Friday's pre-market session, several healthcare stocks experienced significant movement. Gainers included Castle Biosciences (CSTL), ZyVersa Therapeutics (ZVSA), T2 Biosystems (TTOO), Bluejay Diagnostics (BJDX), Longeveron (LGVN), and BiomX (PHGE). Losers included Cadrenal Therapeutics (CVKD), Comera Life Sciences (CMRA), Incannex Healthcare (IXHL), CytoMed Therapeutics (GDTC), Intelligent Bio Solutions (INBS), and Hoth Therapeutics (HOTH).

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 1:12 pm

ZyVersa Therapeutics has been granted a patent by the European Patent Office for its Phase 2a-ready Cholesterol Efflux Mediator VAR 200, intended for use in diabetic nephropathy/diabetic kidney disease. This news has led to an increase in the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 12:35 pm

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) has been granted a patent by the European Patent Office for its Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease. This development could potentially strengthen ZyVersa's position in the biopharmaceutical market.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 11:39 am

ZyVersa Therapeutics has announced a publication in Clinical Immunology that demonstrates a link between renal NLRP3 inflammasome activation and Lupus Nephritis disease activity. The company is developing Inflammasome ASC Inhibitor IC 100, which can inhibit up to 12 different inflammasomes, including NLRP3 inflammasomes.

Portfolio Pulse from Bill Haddad

June 28, 2023 | 11:39 am

Zyversa Therapeutics announced a publication in the Journal of the American Heart Association, linking NLRP3 inflammasomes with calcification in arteries of patients with peripheral arterial disease.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 8:08 pm

On Thursday, 64 companies hit new 52-week lows, with Royalty Pharma being the largest by market cap and Bone Biologics the smallest. Bone Biologics also saw the largest drop, with shares down 54.71%, while Castellum shares bounced back the most, rising 0.0% after hitting a new low.

Portfolio Pulse from Benzinga Insights

June 15, 2023 | 6:53 pm

John Wiley & Sons shares are trading lower by around 10% following Q4 results. Other stocks moving in Thursday's mid-day session include gainers SCWorx Corp., EdtechX Holdings Acquisition Corp. II, and VIQ Solutions Inc., and losers Mersana Therapeutics, Inc., Bone Biologics Corporation, and OncoSec Medical Incorporated.

Portfolio Pulse from Lisa Levin

June 15, 2023 | 5:12 pm

ZyVersa Therapeutics announced that the European Patent Office will grant a patent application covering the company's Phase 2a-ready cholesterol efflux mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 1:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.